Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES | O14684 | 2/20 | 0.47 |
| ▸ | NPY1R | P25929 | 1/20 | 0.36 |
| ▸ | NPY2R | P49146 | 1/20 | 0.36 |
| ▸ | NPY4R | P50391 | 1/20 | 0.36 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.36 |
| ▸ | ACACB | O00763 | 3/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 13/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3002563 | 0.87 | PTGES (0.49) | PTGESNPY1RNPY2RNPY4RNPY5R | |
| SCHEMBL3002560 | 0.87 | PTGES (0.49) | PTGESNPY1RNPY2RNPY4RNPY5R | |
| SCHEMBL3006136 | 0.83 | PTGES (0.44) | PTGESACACBLMNAMAPTHRH3 | |
| SCHEMBL3006135 | 0.83 | PTGES (0.44) | PTGESACACBLMNAMAPTHRH3 | |
| SCHEMBL3578255 | 0.83 | PTGES (0.69) | PTGESNPY1RNPY2RNPY4RNPY5R | |
| SCHEMBL4228938 | 0.82 | PTGES (0.57) | PTGESNPY1RNPY2RNPY4RNPY5R | |
| SCHEMBL3005797 | 0.82 | PTGES (0.47) | PTGESNPY1RNPY2RNPY4RNPY5R | |
| SCHEMBL3001562 | 0.79 | PTGES (0.54) | PTGESACACBLMNAMAPTHRH3 | |
| SCHEMBL3006124 | 0.79 | PTGES (0.49) | PTGESACACBLMNAMAPT | |
| SCHEMBL3576474 | 0.79 | PTGES (0.71) | PTGESACACBHRH3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100197687-A1 | Indoles Useful in the Treatment of Inflammation | BIOLIPOX AB (SE) | 2010-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197687-A1 | Indoles Useful in the Treatment of Inflammation | IDO1, IDO2, TPH1 | PTGES 33/4885NPY1R 6/4885NPY2R 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.